Drugs / autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00509496 | Jun 2007 → Jul 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00509496 ↗ |
| Action | Deplete | “gp100:154-162 TCR transduced T-cells could efficiently kill HLA-A\*0201 positive tumors” NCT00509496 ↗ |
| Modality | Cell therapy | “anti-gp100:154-162 TCR gene-engineered lymphocytes” NCT00509496 ↗ |
| Route | Intravenous | “The cells are infused intravenously over 20-30 minutes” NCT00509496 ↗ |